Advertisement

Antitussiva und Expektorantien

  • Björn Lemmer

Zusammenfassung

Antitussiva und Expektorantien werden bei Husten im Rahmen einer akuten oder chronischen Bronchitis angewendet. Dieses Symptom kann bei einer Reihe ätiologisch unterschiedlicher Krankheiten auftreten, die häufigste Ursache ist eine Virusinfektion in den oberen Atemwegen, wie sie bei Erkältungskrankheiten und Grippe vorkommt. Chronischer Husten ist häufig durch Rauchen bedingt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. American Academy of Pediatrics Committee on Drugs (1997): Use of codeine- and dextromethorphan-containing cough remedies in children. Pediatrics 99: 918–920Google Scholar
  2. Bundesgesundheitsamt (1981): Monographieentwürfe für anthroposophische und phytotherapeutische Arzneimittel. Dtsch Apoth Ztg 52: 2910–2913Google Scholar
  3. Cegla UH (1988): Langzeittherapie über 2 Jahre mit Ambroxol (Mucosolvan) Retardkapseln bei Patienten mit chronischer Bronchitis. Ergebnisse einer Doppelblindstudie an 180 Patienten. Prax Klin Pneumol 42: 715–721Google Scholar
  4. Celli BR, Decramer M, Wedzicha JA, Wilson KC, Augusti A et al (2015): An official Ameriocan Thoracis Society/ European Respiratory Society statement: reseach questions in COPD. Eur Respir J 45: 879–905Google Scholar
  5. Cwientzek U, Ottillinger B, Arenberger P (2011): Acute bronchitis therapy with ivy leaves extracts in a two-arm study. A double-blind, randomised study vs. an other ivy leaves extract. Phytomedicine 18: 1105–1109Google Scholar
  6. Dicpinigaitis PV, Morice AH, Birrung SS, McGarvey L, Smith JA, Canning BJ, Page CP (2014): Antitussive drugs – past, present, and future. Pharmacol Rev 66: 468–512Google Scholar
  7. European Medicines Agency (2011): Community herbal monograph on Hedera helix L., folium. Final assessment report on Hedera helix L., folium. Internet: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/herbal/medicines/herbal_med_000115.jsp&mid=WC-0b01ac058001fa1d
  8. European Medicines Agency (2012): Opinion of the HMPC on a community herbal monograph on Hedera helix L., folium. Internet: http://www.ema-europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_opinion_on_Community_herbal_monograph/2012/01/WC500120649.pdf
  9. European Medicines Agency (2015): Ambroxol and bromhexine expectorants: safety information to be updated. Press Release 25. February EMA/130676/2015Google Scholar
  10. European Medicines Agency (2015): Codein ist bei Kindern unter 12 Jahren nicht zur Behandlung von Husten und Erkältungen anzuwenden. EMA/249413/2015Google Scholar
  11. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017: GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD. Available from: http://www.goldcopd.org
  12. Grandjean EM, Berthet PH, Ruffmann R, Leuenberger PH (2000): Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 22: 209–221Google Scholar
  13. Guyatt GH, Townsend M, Kazim F, Newhouse MT (1987): A controlled trial of ambroxol in chronic bronchitis. Chest 92: 618–620Google Scholar
  14. Jones AP, Wallis C (2010): Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev 2010 Mar 17; (3): CD001127Google Scholar
  15. Kayser O, Kolodziej H (1997): Antibacterial activity of extracts and constituents of Pelargonium sidoides and Pelargonium reniforme. Planta Med 63: 508–510Google Scholar
  16. Kurz H (1986): Expektorantien und Antitussiva. Dtsch Apoth Ztg 126: 1024–1029Google Scholar
  17. Lazaryan M, Shasha-Zigelman C, Dagan Z, Berkovitch M (2015): Codeine should not be prescribed for breastfeeding mothers or children under the age of 12. Act Paediatr 104:555–556Google Scholar
  18. Malerba M, Ponticiello A, Radaeli A, Bensi G, Grassi V (2004): Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Doubleblind, randomised, mulicenter, placebo-controlled study (the AMETHIST Trial). Pulm Pharmacol Therpeut 17: 27–34Google Scholar
  19. Mutschler E, Geisslinger G, Kroemer HK, Menzel S, Ruth P (2013): Arzneimittelwirkungen, 10. Aufl., Wissenschaftliche Verlagsgesellschaft Stuttgart, S. 581–582Google Scholar
  20. Müller S, Jaffan L, Kloiber E, Läer S (2014): Dextrometorphan-Missbrauch bei Jugendlichen: Wie kann sich der Apotheker verhalten? Med Mo Pharm 37: 95–100Google Scholar
  21. Oduwole O, Meremikwu MM, Oyo-Ita A, Udoh EE (2014): Honey for acute cough in children. Cochrane Database Syst Rev Dec 13;12:CD 007094Google Scholar
  22. Olivieri D, Zavattini G, Tomasini G (1987): Ambroxol for the prevention of chronic bronchitis exacerbations: longterm multicenter trial. Respiration 51: Suppl 1, 42–51Google Scholar
  23. Olsson B, Johansson M, Gabrielsson J, Bolme P (1988): Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Eur J Clin Pharmacol 34: 77–82Google Scholar
  24. Øymar K, Skjerven HO, Mikalsen IB (2014): Acute bronchiolitis in infants, a review. Scand J Trauma Resusc Emerg Med 22: 23Google Scholar
  25. Poole P, Chong J, Cates CJ. (2015): Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. Issue 7 Art. No.: CD001287. DOI:  10.1002/14651858.CD001287.pub5
  26. Schmidt M, Thomsen M, Schmidt U (2012): Suitability of ivy extract for the treatment of paediatric cough. Phytother Res 26: 1942–1947Google Scholar
  27. Sharfstein JM, North M, Serwint JR (2007): Over the counter but no longer under the radar – pediatric cough and cold medications. N Engl J Med 357: 2321–2324Google Scholar
  28. Smith SM, Schroeder K, Fahey T (2014): Over-the-counter (OTC) medications for acute cough in children and adults in communitty settings. Cochrane Database Syst Rev Nov 24,11:CD0011831Google Scholar
  29. Stauss-Grabo M, Atiye S, Warnke A, Wedemeyer RS, Donath F, Blume HH. (2010): Observational study on the tolerability and safety of film-coated tablets containing ivy extract (Prospan® Cough Tablets) in the treatment of colds accompanied by coughing. Phytomedicine. 15: 433–436Google Scholar
  30. Timmer A, Günther J, Motschall E, Rücker G, Antes G, Kern WV (2013): Pelargonium sidoides extract for treating acute respiratory tract infections. Cochrane Database Syst Rev. 2013 Oct 22;10:CD006323Google Scholar
  31. Tse HN, Raiteri L, Wong KY, Yee KS, Wai KY, Loo CK, Houng CM. (2013): High-Dose N-acetylcysteine in stable chronic obstructive pulmonary disease: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest 144: 106–118Google Scholar
  32. Virchow JC, Backer V, de Blay F, Kuna P, Ljørring C, Prieto JL, Villesen HH (2015): Defining moderate asthma exacerbations in clinical trials based on ATS/ERS joint statement. Resp Med 109: 547–556Google Scholar
  33. Wark P, McDonald VM (2009): Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev. 2009 Apr 15; (2): CD001506Google Scholar
  34. Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP (2013): Nebulised hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev. 2013 Jul 31; 7: CD006458Google Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Fakultät für Klinische Medizin Mannheim der Universität HeidelbergInstitut für Pharmakologie und ToxikologieMannheimDeutschland

Personalised recommendations